Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Philadelphia Chromosome 2Ovarian Neoplasms 2Neoplasms 2Recurrence 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Leukemia 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1

Interventions

Gemcitabine 5Cisplatin 5Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fluorouracil 4durvalumab 3Taxes 3futibatinib 2fludarabine 2Specimen Handling 2Platinum 2Paclitaxel 2Nivolumab 2Irinotecan 2Folfox protocol 2Fluorodeoxyglucose F18 2Carboplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1ulixertinib 1tocilizumab 1tivozanib 1tislelizumab 1regorafenib 1pevonedistat 1pemigatinib 1pembrolizumab 1olutasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × nilotinib × 30 days × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡